Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences, Inc. (RNA) Income from Continuing Operations (2019 - 2025)

Avidity Biosciences' Income from Continuing Operations history spans 7 years, with the latest figure at 236624000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 130.95% year-over-year to 236624000.0; the TTM value through Dec 2025 reached 682688000.0, down 111.98%, while the annual FY2025 figure was 682688000.0, 111.98% down from the prior year.
  • Income from Continuing Operations reached 236624000.0 in Q4 2025 per RNA's latest filing, down from 174062000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 23841000.0 in Q1 2021 to a low of 236624000.0 in Q4 2025.
  • Average Income from Continuing Operations over 5 years is 75412700.0, with a median of 52212500.0 recorded in 2023.
  • Peak YoY movement for Income from Continuing Operations: crashed 291.8% in 2021, then dropped 2.57% in 2023.
  • A 5-year view of Income from Continuing Operations shows it stood at 38492000.0 in 2021, then tumbled by 31.07% to 50453000.0 in 2022, then fell by 19.59% to 60338000.0 in 2023, then tumbled by 69.81% to 102458000.0 in 2024, then tumbled by 130.95% to 236624000.0 in 2025.
  • Per Business Quant, the three most recent readings for RNA's Income from Continuing Operations are 236624000.0 (Q4 2025), 174062000.0 (Q3 2025), and 156664000.0 (Q2 2025).